Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Redhill Biopharma Ltd (NASDAQ:RDHL)

4.58
Delayed Data
As of Dec 12
 -0.03 / -0.65%
Today’s Change
4.30
Today|||52-Week Range
11.99
-56.21%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$98.1M

Company Description

RedHill Biopharma Ltd. is a biopharmaceutical company, which is focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. The company's gastrointestinal products include Donnatal and EnteraGam. Its clinical-stage pipeline includes TALICIA, RHB-104 ¸ BEKINDA, RHB-106, YELIVA, MESUPRON, and RIZAPORT. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Contact Information

RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv Tel Aviv 64739
P:(723) 541-3131
Investor Relations:

Employees

Shareholders

Other institutional8.29%
Mutual fund holders0.61%
Individual stakeholders--

Top Executives

Dror Ben-AsherChairman & Chief Executive Officer
Gilead RadayChief Operating Officer
Micha Ben-ChorinChief Financial Officer
Reza FathiSenior Vice President-Research & Development
Clara FehrmannDirector-Clinical Operations